US 10525104
Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
granted A61KA61K38/179A61K45/06
Quick answer
US patent 10525104 (Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 3
- CPC classes
- A61K, A61K38/179, A61K45/06, A61P, A61P35/00